Open Mon 8:30am : 01582 842096
Free Delivery on orders over £29
VioVet Insurance

ProZinc Insulin For Cats

  • 10ml Vial £41.29
  • U-40 Syringe » Single £0.35

Selection of 2 products from

£0.35 to £41.29


For the treatment of diabetes mellitus in cats to achieve reduction of hyperglycaemia and improvement of associated clinical signs.

ProZinc 40 IU/ml suspension for injection for cats

Species: Cats Therapeutic indication: Pharmaceuticals: Hormones and therapeutically related products: Others Active ingredient: Insulin Product:ProZinc 40 IU/ml suspension for injection for cats Product index: ProZinc 40 IU/ml suspension for injection for cats


Cloudy, white, aqueous suspension for injection. Each ml contains Insulin human* 40 IU as protamine zinc insulin. One IU (International Unit) corresponds to 0.0347 mg of insulin human. ProZinc is a suspension containing protamine zinc insulin human. *produced by recombinant DNA technology


For the treatment of diabetes mellitus in cats to achieve reduction of hyperglycaemia and improvement of associated clinical signs.

Dosage and administration

Subcutaneous use.


The initial recommended dose is 0.2 to 0.4 IU/kg bodyweight every 12 hours. For cats previously controlled on insulin, a higher starting dose up to 0.7 IU/kg bodyweight may be appropriate. The veterinarian should re-evaluate the cat at appropriate intervals and make adjustments to the treatment protocol, for instance dose and dosing regimen, until adequate glycaemic control has been attained. Any dose adjustment (i.e. increase of dose) should be in general performed after several days (e.g. 1 week) since full action of insulin requires an equilibration phase. Adjustments of insulin dose if required should usually be done between 0.5 to 1 IU per injection. Dose reductions due to observed hypoglycaemia or suspected Somogyi effect (rebound hyperglycaemia) may be of 50% or higher. Once adequate glycaemic control is achieved regular blood glucose control (e.g. every 3 to 4 months or more often) should be performed and further adjustments in the insulin dose might be necessary. Cats can develop diabetic remission, in which case sufficient endogenous insulin production will be regained and exogenous insulin dose will need to be adjusted or ceased.

Method of administration

A U-40 syringe must be used. The suspension should be mixed by gently rolling the vial prior to withdrawing each dose from the vial. The dose should be given concurrently with or immediately after a meal. Particular care should be taken with regard to the accuracy of dosing. The veterinary medicinal product should be administered twice daily by subcutaneous injection. Avoid introduction of contamination during use. After gently rolling the vial, ProZinc suspension has a white, cloudy appearance. A white ring may be seen in the neck of some vials, but this does not affect the quality of the product. Agglomerates (e.g. clumps) can form in insulin suspensions: do not use the product if visible agglomerates persist after gently rolling the vial.

Contra-indications, warnings, etc

Do not use for the acute management of diabetic ketoacidosis. Do not use in case of hypersensitivity to the active substance or to any of the excipients. Very stressful events, concomitant treatment with gestagens and corticosteroids or other concomitant diseases (e.g. infectious or inflammatory or endocrine diseases), might influence insulin effectiveness and therefore the insulin dose may need to be adjusted.

Special precautions for use in animals

The insulin dose may need to be adjusted or discontinued in case of remission of the diabetic state. After the daily insulin dose is established regular glucose monitoring is recommended. Treatment with insulin can cause hypoglycaemia, for clinical signs and appropriate treatment, see below. In a field study to investigate the safety and efficacy of the product, hypoglycaemic events were recorded on at least one occasion in 13% (23 of 176) of treated cats. These events were generally mild in nature. Clinical signs may include hunger, anxiety, unstable locomotion, muscle twitching, stumbling or sinking in the rear legs and disorientation. In this case immediate administration of a glucose solution and/or food is required. Insulin administration should be temporarily stopped and the next dose of insulin adjusted appropriately. Local injection site reactions were very rarely reported and resolved without cessation of therapy. The safety and efficacy of ProZinc in breeding, pregnant and lactating cats has not been evaluated. Use only according to the benefit-risk assessment by the responsible veterinarian. In general, insulin requirements during pregnancy and lactation might be different due to a change in the metabolic state. Therefore, close glucose monitoring and veterinary supervision is advised. Changes in insulin requirements may result from administration of substances which alter glucose tolerance (e.g. corticosteroids and gestagens). Monitoring of glucose concentrations should be performed to adjust the dose accordingly. Similarly, feeding a high protein/low carbohydrate diet may alter insulin requirements (e.g. decrease of insulin dose). An overdose of insulin can result in hypoglycaemia in which case immediate administration of a glucose solution and/or food is required. Clinical signs may include hunger, increasing anxiety, unstable locomotion, muscle twitching, stumbling or sinking in the rear legs and disorientation. Insulin administration should be temporarily stopped and the next dose of insulin adjusted appropriately. The owner is advised to have glucose containing products (e.g. honey, dextrose gel) in the household. In the absence of compatibility studies, this product must not be mixed with other veterinary medicinal products.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

Accidental self-injection can provoke clinical signs of hypoglycaemia and there is a low possibility of an allergic reaction in sensitised individuals. In case of accidental self-injection seek medical advice immediately and show the package leaflet to the physician.

Pharmaceutical precautions

For animal treatment only. To be supplied only on veterinary prescription. Keep out of the sight and reach of children. Shelf life of the veterinary medicinal product as packaged for sale: 2 years. Shelf life after first opening the immediate packaging: 60 days. For unused and broached vials: Store upright in a refrigerator (2 °C – 8 °C). Do not freeze. Keep the vial in the outer carton in order to protect from light. Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Legal category

Legal category: POM-V

Packaging quantities

Cardboard box with 1 clear glass vial of 10 ml closed with a butyl rubber stopper and sealed with a plastic flip-off cap.

Further information

Pharmacodynamic properties

Insulin activates insulin receptors and therewith a complex cell signaling cascade which results in increased glucose uptake into the cells. The main effects of insulin are the reduction in circulating blood glucose concentrations and the storage of fat. Overall insulin influences the regulation of the carbohydrate and fat metabolism. Under clinical field conditions in diabetic cats the maximal action on blood glucose concentrations (e.g. blood glucose nadir) after subcutaneous administration was observed at a mean of 6 hours (range 3 to 9 hours). In the majority of cats the glucose lowering effect lasted for a minimum of 9 hours after first insulin injection.

Pharmacokinetic particulars

Absorption: Protamine zinc recombinant human insulin is an insulin whose absorption and onset of action is delayed by the addition of protamine and zinc leading to crystal formation. After subcutaneous injection, proteolytic tissue enzymes degrade protamine to permit the absorption of insulin. In addition, interstitial fluid will dilute and break down the formed zinc insulin hexamer complexes and result in a delayed absorption from the subcutaneous depot. Distribution: Once absorbed from the subcutaneous site, insulin will enter the circulation and diffuse into tissues, where it binds to insulin receptors found on most tissues. Target tissue organs are i.e. liver, muscle and adipose tissue. Metabolism: Following the binding of insulin with the insulin receptor and the subsequent action, insulin is released back into the extracellular environment. It may then be degraded on passage through the liver or by the kidney. Degradation normally involves endocytosis of the insulin-receptor complex, followed by the action of insulin-degrading enzyme. Elimination: The liver and the kidney are the two main organs which eliminate insulin from the circulation. Forty per cent of insulin is eliminated by the liver and 60% is eliminated by the kidney.

Marketing Authorisation Holder (if different from distributor)

Boehringer Ingelheim Vetmedica GmbH Binger Strasse 173 55216 Ingelheim/Rhein Germany

Marketing Authorisation Number


Significant changes


GTIN description:ProZinc 40 IU/ml suspension for injection for cats GTIN:5012917025279

Need help or advice? Contact us:

  • Landline: 01582 842096
  • Freephone*: 0800 084 2608
  • Mon - Fri: 8:30am - 6:00pm
  • Sat: 9:00am - 1:00pm
  • Email:

All prices include VAT where applicable. *The freephone number is free from most UK landlines only, mobiles are usually charged so we'd recommend calling our landline from your mobile or internationally.

Reviews of ProZinc Insulin For Cats

Read our customers' reviews of ProZinc Insulin For Cats

Questions & Answers for ProZinc Insulin For Cats

There are currently no questions for ProZinc Insulin For Cats - be the first to ask one!

Ask A Question